8-K: AirSculpt Technologies Reports Mixed Q1 Results with Revenue Growth Offset by EBITDA Decline

AirSculpt Technologies announced a 3.9% increase in revenue to $47.6 million for the first quarter of 2024, alongside a net income of $6.0 million, but experienced a decline in adjusted EBITDA.

Summary

• AirSculpt Technologies reported a 3.9% increase in revenue to $47.6 million for the first quarter of 2024, compared to $45.8 million in the same period last year.
• The company's case volume grew by 2.9% year-over-year, reaching 3,746 cases.
• Net income for the quarter was $6.0 million, a significant improvement from a net loss of $0.0 million in the prior year period.
• However, adjusted EBITDA decreased to $7.3 million from $9.5 million in the prior year period.
• The company experienced softness in same-store performance due to macroeconomic headwinds, but new locations are performing above internal projections.
• AirSculpt is maintaining its full-year 2024 guidance, projecting approximately $220 million in revenue and $50 million in adjusted EBITDA.
• Six new centers are planned to open in the second half of 2024.
• The company had $11.0 million in cash and cash equivalents and $5.0 million of borrowing capacity as of March 31, 2024.
• Operating cash flow for the quarter was $3.4 million, down from $6.2 million in the same period last year.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While revenue and net income improved, the decline in adjusted EBITDA and operating cash flow raises concerns. The company is maintaining guidance, which is a positive, but the macroeconomic headwinds and increased competition are risks.

Positives

• Revenue increased by 3.9% year-over-year, reaching $47.6 million.
• Net income was $6.0 million, a significant improvement from a net loss in the prior year period.
• Case volume increased by 2.9% to 3,746 cases.
• New locations are outperforming internal projections, indicating strong growth potential.
• The company is maintaining its full-year 2024 revenue and adjusted EBITDA guidance.
• The company has $11.0 million in cash and cash equivalents and $5.0 million of borrowing capacity.

Negatives

• Adjusted EBITDA decreased to $7.3 million from $9.5 million in the prior year period.
• Same-store performance was affected by macroeconomic headwinds.
• Operating cash flow decreased to $3.4 million from $6.2 million in the same period last year.
• The company experienced a decline in adjusted EBITDA margin from 20.6% to 15.4%.

Risks

• The company faces risks related to opening and operating new centers in a timely and cost-effective manner.
• Rising interest rates and inflation could impact the ability to open new centers and increase operating expenses.
• Increased competition in the weight loss and obesity solutions market, including the rise of weight-loss drugs, poses a threat.
• Shortages or quality control issues with third-party manufacturers or suppliers could affect operations.
• Competition for surgeons and potential litigation or medical malpractice claims are ongoing risks.
• Changes in laws governing the corporate practice of medicine or fee-splitting could impact the business.
• Macroeconomic conditions, including inflation and the threat of recession, could affect the company's performance.
• Business disruptions from war, pandemic, terrorist acts, or political unrest are potential risks.

Future Outlook

The company is maintaining its full-year 2024 guidance, projecting approximately $220 million in revenue and $50 million in adjusted EBITDA. Six new centers are planned to open in the second half of 2024.

Management Comments

• We grew revenues about 4% in the quarter driven by the de novo locations we opened in the prior year.
• These centers continue to outpace our internal projections and give us even greater confidence in our 2024 openings.
• Consistent with other companies in aesthetics and high-end retail, we experienced softness due to macro-economic headwinds; which affected our same store performance.
• Despite this, we continued to invest in customer acquisition and awareness-building initiatives, which drove most of our decline in adjusted EBITDA over the comparable period.
• As a result of these investments, we are already seeing signs of improved lead traffic and look forward to stronger performance as the year progresses.

Industry Context

The company acknowledges experiencing similar macroeconomic headwinds as other companies in the aesthetics and high-end retail sectors, indicating a broader industry trend affecting consumer spending and same-store performance. The company is also facing increased competition in the weight loss and obesity solutions market.

Comparison to Industry Standards

• While AirSculpt's revenue growth of 3.9% is positive, the decline in adjusted EBITDA suggests potential challenges in operational efficiency or cost management compared to industry peers.
• Companies like InMode and Cutera, which also operate in the aesthetic device and procedure market, have reported varying results, with some showing stronger EBITDA growth, indicating that AirSculpt's performance may be lagging in this area.
• The company's focus on de novo locations is a common growth strategy in the industry, but the success of these locations will be crucial for future performance.
• The impact of macroeconomic headwinds on same-store performance is a shared challenge across the industry, but the extent of the impact varies by company.

Stakeholder Impact

• Shareholders may be concerned about the decline in adjusted EBITDA and operating cash flow.
• Employees may be affected by the company's performance and future growth plans.
• Customers may benefit from the expansion of new centers and continued investment in customer acquisition.
• Suppliers may be impacted by the company's financial performance and operational decisions.
• Creditors may be monitoring the company's cash flow and debt levels.

Next Steps

• The company plans to open six new centers in the second half of 2024.
• AirSculpt will hold a conference call on May 10, 2024, to discuss the results.

Key Dates

Keywords

AirSculpt, body contouring, revenue, EBITDA, net income, case volume, financial results, growth, aesthetics, de novo, macroeconomic headwinds